drugset / Trial / NCT05195944

Semaglutide vs Sitagliptin

NCT05195944

Phase 4 Enrolling by invitation 58 enrolled University Health Network, Toronto Novo Nordisk A/S · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The effect of once daily dosing of oral Semaglutide versus once daily dosing Sitagliptin on glycemic control, body weight, and safety and tolerability will be compared in Liver Transplant Recipients with poorly-controlled Diabetes Mellitus.

Timeline

Start
2022-10-26
Primary completion
2026-12
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Semaglutide Peptide 14 mg Oral
Comparator Sitagliptin Small molecule 100 mg